Introduction And Background

Type 1 diabetes mellitus (T1DM) is characterized by defects in beta-cell function that eventually result in absolute insulin deficiency, requiring insulin replacement therapies to ensure survival and limit the complications of hyperglycemia. Type 1A or autoimmune diabetes, which accounts for 85% to 90% of T1DM, is characterized by the presence of autoantibodies to several islet cell molecules, including insulin, GAD, and IA-2, as well as by infiltration of the islets and destruction of beta cells by mononuclear cells (insulitis). Although the presence of insulitis requires a tissue specimen for diagnosis, autoantibodies on the other hand can be measured from serum and are detectable years prior to the onset of hyperglycemia. Along with genetic screening and assessment of stimulated insulin secretion, autoantibodies can also be used to predict the development of T1DM in at-risk populations.

Although there is a 10- to 15-fold increase in the lifetime risk of developing the disease for first-degree relatives of subjects with T1DM compared to the general population, over 85% of patients who develop autoimmune diabetes do so in the absence of a positive family history. Several genetic factors that increase the risk of developing autoimmune diabetes have been identified; the best characterized and studied are the DR3/DR4 alleles in the MHC (HLA) complex. It is still unclear what triggers the initial immunologic attack on the beta cell, but a combination of both genetic and environmental factors is likely to be involved. Once autoantibodies are detectable in the serum, many of these patients will go on to develop insulitis and beta-cell destruction eventually leading to metabolic instability, hyperglycemia, and possibly ketoacidosis. The mechanisms underlying the progression of the autoimmune attack on the beta cells have been extensively assessed in the rodent model, but unfortunately remain incompletely understood in humans, where access to injured tissue (pancreatic islet cells) and other factors have limited our ability to better address the pathology of diabetes. In this chapter, we will review the natural history and the development of the metabolic abnormalities that characterize the progression of autoimmune diabetes and try to link these clinical observations to possible pathogenetic factors. We will conclude by describing the relationship of T1DM to other autoimmune syndromes that share similar genetic predisposition.

Table 1 HLA Haplotypes and Risk of Type 1 Diabetes (86)

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook

Post a comment